Ewin Tang - Breakthrough in Mathematics

Ewin Tang Youngest Winner of Breakthrough Prize in Mathematics

Ewin Tang (born 2000) is a computer scientist at the University of California, Berkeley. She was named as one of 2019 Science Forbes 30 Under 30 for her work developing classical algorithms which matched the performance of the fastest known quantum algorithms, done as an undergraduate under the supervision of Scott Aaronson.

In 2017 Tang took a class on quantum computing from Scott Aaronson, who recognized her as an "unusually talented student" and became her undergraduate thesis adviser. Tang eventually developed a new classical algorithm for a matrix completion problem, motivated by applications to recommendation systems. The algorithm became the basis of her undergraduate thesis A quantum-inspired classical algorithm for recommendation systems and she received a BS in computer science and pure mathematics from UT Austin in 2018.

In 2023 Tang completed her Ph.D. in theoretical computer science at the University of Washington under the supervision of James Lee where she continued her undergraduate work on quantum-inspired classical algorithms for other problems, such as principal component analysis and low-rank stochastic regression...Wikipedia

Quantum advantage was supposed to be the ultimate proof that quantum machines could revolutionize global commerce, but 18-year-old Ewin Tang had other plans. In 2018, she presented a classical algorithm that matched the speed of a billion-dollar quantum promise, effectively "dequantizing" one of the industry's most cited commercial use cases. In this video, we go inside the Berkeley seminar room where Tang challenged elite physicists and computer scientists with her homework—an assignment that backfired in the best way possible....

Ewin Tang
Born	2000 (age 25–26)
Alma mater	University of Texas at Austin (BS) University of Washington (PhD)
Awards	Maryam Mirzakhani New Frontiers Prize (2025)
Scientific career
Fields	Theoretical computer science Quantum computing
Doctoral advisor	James Lee
Other academic advisors	Scott Aaronson
Website	https://ewintang.com/

You May Like:

Old Hong Kong 老香港

Taiwan Island 台灣環島

Stage 3b CKD 慢性腎臟病

Stage 3 Chronic Kidney Disease 慢性腎臟病Reversal of Stage 3b chronic kidney disease (CKD) is usually not possible, but you can often slow it down significantly—and sometimes even stabilize or slightly improve kidney function if the cause is addressed early and aggressively.

What “Stage 3b CKD” means

Stage 3b CKD corresponds to an estimated GFR of 30–44 mL/min, meaning moderate-to-severe loss of kidney function. At this stage, preventing further decline becomes the priority.

When improvement is possible

Some people see partial improvement if the underlying issue is reversible or treated well, such as:

Poorly controlled Type 2 Diabetes
High blood pressure (Hypertension)
Medication-related kidney stress (e.g., NSAIDs like Ibuprofen)
Dehydration or obstruction (e.g., kidney stones)

If those are corrected, kidney function can bounce back somewhat, but usually not to completely normal levels.

What actually works: slowing or halting progression

1. Control blood pressure (most important)

Target often: <130/80
Common protective medications:
- Lisinopril, Losartan (ACE inhibitors / ARBs)
These don’t just lower BP—they protect kidney filtration units

2. Control blood sugar (if diabetic)

Aim for stable A1C (often ~6.5–7.5 depending on age)
Newer drugs can protect kidneys:
- Empagliflozin (SGLT2 inhibitor)
- Dapagliflozin

These have shown real slowing of CKD progression, even in non-diabetics.

3. Reduce protein in urine

Protein leakage accelerates kidney damage. ACE inhibitors/ARBs + SGLT2 inhibitors help reduce this.

4. Diet changes (high impact)

Moderate protein intake (not high-protein diets)
Lower sodium (≈ <2g/day)
Manage potassium & phosphorus if elevated
Emphasize:
- Vegetables, fruits (within potassium limits)
- Whole foods over processed foods

A renal dietitian can make a big difference here.

5. Avoid kidney stressors

Limit NSAIDs (like Ibuprofen, naproxen)
Be cautious with contrast dyes (CT scans)
Avoid dehydration
Review supplements (some herbs are harmful)

6. Treat underlying causes

Depending on diagnosis:

Glomerulonephritis
Polycystic kidney disease
Obstruction
Autoimmune diseases

Some require specialized treatments or immunotherapy

7. Lifestyle factors

Maintain healthy weight
Regular physical activity
Stop smoking
Good sleep

Can kidneys regenerate?

Unlike liver cells, kidneys have very limited regenerative ability. Damage tends to be permanent, but remaining function can compensate if protected.

Realistic expectations

✔ Slow decline: very achievable
✔ Stabilization for years: possible
✔ Small improvement in eGFR: sometimes
✖ Full reversal: uncommon

Many patients stay in Stage 3 for years or decades with proper care.

When to see a specialist

A nephrologist is strongly recommended at Stage 3b to:

Tailor medications
Monitor progression
Prevent complications (anemia, bone disease)

Bottom line

Think of this less as “reversing” and more as:

“Protect what’s left and stop further damage.”

That strategy can dramatically change long-term outcomes.

If you want, I can:

Review your lab values (eGFR, creatinine, urine protein)
Suggest a sample kidney-friendly meal plan
Or outline latest treatments (including emerging therapies)

Here’s a practical, kidney-friendly 1-day meal plan tailored for Stage 3b Chronic Kidney Disease. The goal is to reduce kidney workload, control blood pressure, and limit protein, sodium, and phosphorus—while still eating well.

🥗 Sample Kidney-Friendly Meal Plan (Stage 3b)

🌅 Breakfast

Oatmeal (½–1 cup cooked) with:
- Blueberries or strawberries
- Small handful of walnuts
1 slice whole-grain toast with olive oil or avocado spread
Tea or coffee (limit sugar)

👉 Why this works:
Oats are lower in protein and phosphorus, and berries are kidney-safe fruits.

🍎 Mid-morning snack

Apple or pear
Small handful of unsalted almonds (≈10–12)

🍽️ Lunch

Grilled chicken breast (3 oz) (moderate protein portion)
White or brown rice (1 cup)
Steamed vegetables:
- Green beans
- Carrots
Side salad (lettuce, cucumber, olive oil + vinegar)

👉 Tip: Keep sodium low—avoid bottled dressings.

☕ Afternoon snack

Plain yogurt (if phosphorus is okay in your labs)
OR
Rice cakes with peanut butter (thin layer)

🌙 Dinner

Baked salmon (3 oz) or tofu
Quinoa or rice (½–1 cup)
Steamed zucchini + bell peppers
Small side of fruit (e.g., grapes)

🌜 Optional evening snack

Crackers (low sodium)
Herbal tea

⚖️ Key Kidney Diet Principles (Stage 3b)

1. Protein: Moderate (not high)

Aim: ~0.6–0.8 g/kg/day
Avoid high-protein diets (keto, bodybuilding diets)

2. Sodium: Keep it low

Target: <2,000 mg/day
Avoid:
- Processed foods
- Canned soups
- Fast food

3. Potassium: Monitor (depends on labs)

Not all CKD patients need restriction yet.

Lower-potassium options:

Apples, berries, grapes
Green beans, cabbage, zucchini

Be cautious with:

Bananas, oranges, potatoes, tomatoes

4. Phosphorus: Reduce if elevated

Limit:

Processed foods (hidden phosphorus additives)
Dark colas
Large amounts of dairy

5. Fluids

Usually normal intake unless your doctor restricts it

🚫 Foods to Limit or Avoid

Processed meats (bacon, sausage)
Fast food / restaurant-heavy diet
Salty snacks
Excess red meat
NSAIDs like Ibuprofen (not food, but important)

👍 What helps protect kidney function

Olive oil over butter
Plant-forward meals
Consistent blood pressure control (important for Hypertension)
Stable blood sugar if you have Type 2 Diabetes

🧠 Important nuance

Kidney diets are not one-size-fits-all:

If potassium is high → stricter fruit/vegetable choices
If phosphorus is high → more dietary restriction
If weight loss is needed → calorie adjustment

Bottom line

This type of diet can:

Slow CKD progression
Reduce symptoms
Improve long-term outcomes

Here’s a 7-day kidney-friendly meal plan tailored for Stage 3b Chronic Kidney Disease. It keeps protein moderate, sodium low, and potassium/phosphorus balanced for most people at this stage (adjustments may be needed once I see your labs).

🗓️ 7-Day Kidney-Friendly Meal Plan

Day 1

Breakfast: Oatmeal + blueberries + walnuts
Lunch: Grilled chicken (3 oz), rice, green beans
Dinner: Baked salmon, quinoa, zucchini
Snacks: Apple, unsalted almonds

Day 2

Breakfast: Whole-grain toast + avocado + boiled egg
Lunch: Turkey lettuce wrap + cucumber salad
Dinner: Stir-fried tofu + cabbage + carrots + rice
Snacks: Pear, rice cakes

Day 3

Breakfast: Greek yogurt (small portion) + strawberries
Lunch: Grilled shrimp salad (olive oil + vinegar)
Dinner: Chicken soup (low sodium) + noodles + bok choy
Snacks: Grapes, crackers

Day 4

Breakfast: Oatmeal + sliced apple + cinnamon
Lunch: Quinoa bowl with roasted vegetables
Dinner: Baked cod + rice + steamed broccoli (moderate portion)
Snacks: Peach, almonds

Day 5

Breakfast: Smoothie (berries + almond milk)
Lunch: Chicken sandwich (low-sodium bread, lettuce)
Dinner: Tofu + mushroom stir-fry + rice
Snacks: Apple slices + peanut butter

Day 6

Breakfast: Scrambled eggs (1–2) + toast
Lunch: Lentil soup (small portion) + salad
Dinner: Grilled fish tacos (corn tortillas, cabbage slaw)
Snacks: Yogurt or rice cakes

Day 7

Breakfast: Oatmeal + banana slices (small portion)
Lunch: Cold noodle salad with shredded chicken
Dinner: Steamed fish (Asian style) + rice + spinach (moderate portion)
Snacks: Berries, crackers

🍽️ Practical Tips to Make This Work

✔ Protein control (very important)

Keep portions ≈ 3 oz per meal
Mix in plant proteins (tofu, lentils in small amounts)

✔ Sodium control

Cook at home when possible
Use:
- Garlic, ginger, vinegar, herbs
Limit soy sauce (use low-sodium, small amounts)

✔ Smart Asian-style swaps (if you prefer)

White rice > fried rice
Steamed fish > braised/sauced dishes
Clear soups > heavy broths
Stir-fry with minimal oil/salt

✔ Potassium awareness (depends on labs)

Rotate fruits:

Safer: apples, berries, grapes
Limit: bananas, oranges, tomatoes

✔ Phosphorus awareness

Limit processed foods
Be cautious with excess dairy

⚠️ What to watch

Avoid high-sodium foods
Avoid frequent NSAIDs like Ibuprofen
Control Hypertension and Type 2 Diabetes if present

🧠 Final thought

This plan is kidney-protective but flexible—the real optimization comes when we align it with:

Your potassium level
Your urine protein
Your trend in eGFR

Here’s your 7-day Chinese-style kidney-friendly menu tailored for Stage 3b Chronic Kidney Disease. It keeps the same principles—moderate protein, low sodium, balanced potassium/phosphorus—but uses familiar Chinese dishes and cooking styles (steamed, clear soups, light stir-fry).

Best Kidney vegetables: Onion, Egg Plant, Garlic, Cabbage, Bean

🗓️ 7-Day Chinese-Style Kidney-Friendly Menu

Day 1

早餐：燕麥粥 + 藍莓 + 核桃
午餐：清蒸雞胸（約3兩）+ 白飯 + 蒜蓉四季豆
晚餐：清蒸三文魚 + 藜麥/白飯 + 清炒西葫蘆
加餐：蘋果、無鹽杏仁

Day 2

早餐：全麥吐司 + 牛油果 + 水煮蛋
午餐：生菜雞肉包（少鹽）+ 涼拌黃瓜
晚餐：家常豆腐（少鹽）+ 白菜炒胡蘿蔔 + 白飯
加餐：梨、米餅

Day 3

早餐：低糖酸奶 + 草莓
午餐：蝦仁沙拉（橄欖油+醋）
晚餐：清雞湯麵（低鈉）+ 小白菜
加餐：葡萄、蘇打餅

Day 4

早餐：蘋果肉桂燕麥粥
午餐：藜麥素菜碗（烤/炒時少油少鹽）
晚餐：清蒸鱈魚 + 白飯 + 西蘭花（適量）
加餐：桃子、少量堅果

Day 5

早餐：莓果杏仁奶奶昔
午餐：低鈉雞肉三明治（中式可改為雞絲涼麵）
晚餐：香菇豆腐煲（少鹽）+ 白飯
加餐：蘋果 + 花生醬（薄塗）

Day 6

早餐：炒蛋（1–2個）+ 吐司
午餐：紅豆/扁豆湯（小份）+ 涼拌菜
晚餐：清蒸魚 + 玉米餅/薄餅 + 高麗菜絲
加餐：酸奶或米餅

Day 7

早餐：白粥 + 小菜（低鈉）+ 半根香蕉
午餐：雞絲涼麵（少鹽醬汁）
晚餐：薑蔥蒸魚 + 白飯 + 清炒菠菜（適量）
加餐：莓果、餅乾

🍜 關鍵中式飲食調整技巧

✔ 1. 烹調方式（非常重要）

優先選擇：

清蒸
汆燙
清炒（少油）
燉湯（避免濃湯/老火湯過鹹）

👉 避免：

紅燒、滷味（鈉高）
重口味爆炒

✔ 2. 控鹽（核心）

每日鈉目標：約 <2000 mg
減少：
- 醬油（改低鈉，少量）
- 蠔油、豆瓣醬
用替代：
- 薑、蒜、蔥、醋、香油（少量）

✔ 3. 蛋白質（適量即可）

每餐約「手掌大小」（≈3兩）
優先：
- 魚、雞、豆腐
減少：
- 紅肉、加工肉

✔ 4. 鉀管理（依化驗調整）

較安全：

蘋果、梨、莓果
青菜、白菜、絲瓜

需控制：

香蕉、番茄、馬鈴薯

✔ 5. 磷管理

少吃加工食品
控制奶製品
留意「添加磷」（包裝食品）

⚠️ 特別提醒

避免長期使用止痛藥如 Ibuprofen
穩定控制 Hypertension 和 Type 2 Diabetes（若有）

🧠 實際關鍵

這套中式飲食如果做對，可以：

減少腎臟負擔
降低蛋白尿
延緩腎功能下降

Here is a clear, up-to-date overview of latest and emerging treatments for chronic kidney disease (CKD)—including what is already standard today and what is newly emerging in 2025–2026 research and approvals.

This is especially relevant for Stage 3b Chronic Kidney Disease, where the goal is to slow progression, reduce protein loss, and prevent kidney failure, not “reverse” damage.

🧠 1. Current “Foundation” Therapies (Standard of Care)

These are the core treatments every CKD patient should be evaluated for:

🩺 Blood pressure & kidney protection drugs

ACE inhibitors / ARBs
- e.g. Lisinopril, Losartan
Effects:
- Lower blood pressure
- Reduce protein in urine
- Slow kidney scarring

👉 Still considered the foundation of CKD therapy

💊 2. Major Breakthrough Class (Game-Changers)

🔵 SGLT2 inhibitors (largest impact in 30 years)

Empagliflozin, Dapagliflozin, canagliflozin

What they do:

Slow kidney function decline
Reduce heart failure risk
Lower hospitalization and mortality risk

Key insight:

Work even in non-diabetic CKD
Now used broadly for CKD with albuminuria

📊 Evidence shows ~30–40% reduction in risk of kidney failure progression in trials (National Kidney Foundation)

🟣 Non-steroidal MRA (finerenone)

Finerenone

What it does:

Reduces inflammation + fibrosis in kidneys
Lowers proteinuria
Protects heart + kidneys together

Best use:

CKD with Type 2 diabetes

📊 Shows strong reduction in CKD progression + cardiovascular events (Frontiers)

🧩 Combination therapy (important new trend)

SGLT2 inhibitor + finerenone together

Why it matters:

Additive kidney protection
Lower mortality risk in real-world studies (OUP Academic)

👉 This is becoming a new “standard combo strategy”

🆕 3. Newest Emerging Therapies (2025–2026)

These are reshaping CKD care:

🟠 GLP-1 receptor agonists (kidney + metabolic protection)

Semaglutide (Ozempic)
Tirzepatide

Effects:

Reduce weight and inflammation
Improve blood sugar control
Reduce kidney disease progression risk

📊 Now FDA-recognized for CKD risk reduction in diabetes patients (PR Newswire)

🟡 Dual and triple therapy approach (emerging paradigm)

Doctors are increasingly combining:

ACEi/ARB
SGLT2 inhibitors
Finerenone
GLP-1 agents (when diabetes/obesity present)

👉 Goal: multi-pathway kidney protection

🔬 4. Disease-specific precision therapies (fast-growing area)

These are for specific kidney diseases, not general CKD:

Examples:

IgA nephropathy drugs (e.g. sparsentan)
Complement inhibitors (C3 glomerulopathy)
Autoimmune kidney disease biologics

📊 2025 saw multiple FDA approvals for rare kidney diseases (Liv Hospital)

🧪 5. Anemia & complication treatments (supportive care evolution)

CKD anemia therapies:

Oral HIF stabilizers (e.g. vadadustat)
New ESA alternatives

👉 Less injection burden, more oral options emerging

🧬 6. Pipeline / Experimental Therapies

These are still in trials but promising:

1. Anti-fibrosis drugs

Target kidney scarring directly

2. Endothelin receptor antagonists

Reduce inflammation + protein leakage

3. Regenerative medicine approaches

Stem cell and repair signaling research (early stage)

4. Multi-drug combination optimization

“Precision nephrology” using biomarker-guided therapy

🧭 7. What this means for Stage 3b CKD

For someone at your stage, the modern strategy is:

🧱 Step 1: Stabilize foundation

BP control (ACEi/ARB)

🚀 Step 2: Add kidney-protective agents

SGLT2 inhibitor (almost standard now)

🛡 Step 3: Add second protective layer if needed

Finerenone (especially if proteinuria)

🔄 Step 4: Add metabolic protection if applicable

GLP-1 drugs if diabetes/obesity

🧠 Bottom line

We are in a new era of CKD treatment:

❌ Old approach: wait for decline → dialysis planning
✅ New approach: multi-drug kidney protection to slow or delay failure for decades

🌍 🥇 Tier 1: Global Leaders (Most Advanced Lung Cancer Centers)

These are widely considered the top 3–5 institutions in the world for lung cancer care.

🇺🇸 1. MD Anderson Cancer Center (Houston)

One of the largest thoracic oncology programs globally
Leader in:
- Genomic-driven therapy (EGFR, ALK, KRAS, etc.)
- Immunotherapy combinations
- Proton therapy + advanced radiation
Extremely high clinical trial access
Strong outcomes in advanced and complex cases
Often ranked #1 cancer center worldwide in oncology surveys (Cadena SER)

👉 Best for:

Advanced/metastatic lung cancer
Rare mutations
Patients seeking cutting-edge trials

🇺🇸 2. Memorial Sloan Kettering Cancer Center (MSK) – New York

One of the most specialized thoracic oncology programs globally
Known for:
- Precision medicine
- Complex surgical lung cancer cases
- Minimal-invasive thoracic surgery leadership
- Highly structured multidisciplinary tumor boards
One of the highest-volume thoracic surgery centers in the US (Memorial Sloan Kettering)

👉 Best for:

Surgical candidates (early–stage to locally advanced)
Second opinions for complex cases
Precision oncology + trials

🇺🇸 3. Mayo Clinic (Rochester + multi-campus US)

Extremely high-volume lung cancer program (~thousands/year)
Strong reputation for:
- Early detection + screening
- Robotic and minimally invasive surgery
- Integrated multidisciplinary care
NCI-designated Comprehensive Cancer Center
Consistently strong survival outcomes in large datasets (Mayo Clinic)

👉 Best for:

Balanced care (surgery + systemic therapy)
Complex comorbid patients
Patients wanting highly coordinated care

🌏 🥈 Tier 2: Global Excellence Centers (Very Strong International Options)

🇫🇷 Gustave Roussy (Paris, France)

One of Europe’s top cancer centers
Strong in:
- Immunotherapy
- Early-phase clinical trials
- Personalized oncology programs

👉 Best for:

Access to European trials
Advanced systemic therapy options

🇬🇧 The Royal Marsden (London, UK)

UK’s leading cancer hospital
Strong thoracic oncology + radiation oncology programs
Close collaboration with Institute of Cancer Research

👉 Best for:

UK/EU clinical trials
Advanced radiation therapy

🇰🇷 Samsung Medical Center (Seoul, Korea)

One of Asia’s top cancer institutions
Very advanced:
- Early detection programs
- Fast access to targeted therapy
- High-volume thoracic surgery

👉 Best for:

Asian patients seeking fast diagnosis/treatment pathways
High-tech integrated care systems

🇯🇵 National Cancer Center Hospital (Tokyo, Japan)

Strong surgical oncology tradition
Excellent early-stage lung cancer outcomes
Advanced screening programs

🇨🇳 Leading China Centers (rapidly advancing)

Beijing Cancer Hospital (Peking University Cancer Hospital)
Shanghai Chest Hospital
Fudan University Shanghai Cancer Center

Strengths:

Very large patient volumes
Fast adoption of targeted therapy and immunotherapy
Strong surgical expertise in thoracic oncology

Limitations:

Clinical trial access for global novel drugs can vary

📊 Big Picture Comparison

Tier	Centers	Strength
🥇 Tier 1	MD Anderson, MSK, Mayo Clinic	Best global outcomes + trials + multidisciplinary care
🥈 Tier 2	Gustave Roussy, Royal Marsden, Samsung, NCC Japan	Excellent regional leaders + strong trials
🇨🇳 Rapid growth	Top China cancer centers	High volume, fast innovation adoption

🧠 Practical Insight (important)

Across studies and clinical practice:

Best survival outcomes correlate more with “center volume + specialization” than country
Patients at top-tier centers often gain:
- More precise molecular testing
- More clinical trial access
- Better surgical staging accuracy
- More personalized therapy sequencing

Here’s a clear, data-driven breakdown of PD-1 / PD-L1 immunotherapy outcomes in lung cancer (especially Lung cancer), focusing on what actually matters clinically: response rates, survival, and what “success” really means today.

🧬 1. How PD-1 / PD-L1 immunotherapy works

These drugs (e.g., pembrolizumab, nivolumab, atezolizumab) block the “brakes” on immune cells.

Tumors express PD-L1 to “hide” from immune attack
Drugs block PD-1 (immune cell) / PD-L1 (tumor cell) interaction
This allows T-cells to attack cancer again

👉 Key idea: it is not directly killing cancer, but reactivating immune control.

📊 2. Success Rates (Real-World Averages)

🟡 A. Response rates (tumor shrinkage)

1st-line metastatic NSCLC (no selection):

~20–35% response rate overall

If PD-L1 high (≥50% expression):

~40–50% response rate
Some trials (e.g., pembrolizumab monotherapy) ~45% response rate in this group (Cancer.gov)

If PD-L1 low (<1%):

Often <10–15% response rate

🧠 Interpretation:

Only a subset of patients “shrink dramatically”
But responders can have very long-lasting benefit

⏳ 3. Survival Outcomes (Where immunotherapy really changed the game)

🟢 Overall survival benefit vs chemotherapy

Meta-analysis of PD-1/PD-L1 inhibitors in NSCLC:

~27% reduction in risk of death
Hazard ratio ~0.73 vs chemo (PubMed)

🟡 5-year survival (modern era)

PD-L1 ≥50%, pembrolizumab monotherapy:

~30–32% 5-year survival (Frontiers)

👉 This is the key breakthrough:

Historically: ~5–10% long-term survival in metastatic lung cancer
Now in selected patients: ~1 in 3 alive at 5 years

🔴 PD-L1 low / unselected metastatic disease:

~10–20% long-term survival (varies heavily with combination chemo + immunotherapy)

🧪 4. Why “response rate” ≠ “success rate”

This is critical in immunotherapy:

❗ Two patterns exist:

1. Non-responders (~60–80%)

No major tumor shrinkage
Disease progresses within months

2. Responders (~20–40%)

Tumor shrinkage or stability
Can last:
- 2–5+ years
- Sometimes durable remission-like state

👉 This is why immunotherapy looks “low response but high impact”

🧬 5. Factors that strongly affect success

🔵 PD-L1 expression (strongest clinical predictor)

≥50% → best outcomes
1–49% → intermediate
<1% → lower benefit

🔵 Tumor mutational burden (TMB)

High TMB → better immune visibility → better response

🔵 Smoking-related cancers

Often more mutations → better immunotherapy response

🔵 Driver mutations (important exception)

EGFR / ALK cancers:
- Usually less responsive to PD-1 alone
- Better treated first with targeted therapy

💊 6. Immunotherapy combinations (modern standard)

Today most patients receive:

🔹 Chemo + PD-1 inhibitor

Response rate: ~45–60%
Better for low PD-L1 patients

🔹 Immunotherapy alone (high PD-L1)

Less toxicity
Durable responders in subset

📈 7. The “big picture” transformation

Before immunotherapy:

Median survival: ~8–12 months (stage IV NSCLC)

Now (selected patients):

Median survival: 2–4+ years
Long-term survivors: 10–30% depending on biomarker profile

🧠 8. Key takeaway (simple version)

~1/4 to 1/3 of patients respond meaningfully
~10–30% achieve long-term survival
PD-L1 ≥50% = best chance of durable benefit
Immunotherapy is less predictable, but can produce long remissions not seen in chemotherapy

If you want to go deeper

I can break this further into:

🧬 “Why some patients are cured-like responders”
🧠 PD-L1 0% vs 50% vs 90% real-world outcomes
💊 Best immunotherapy regimens today (KEYNOTE / IMpower / CheckMate)
🏥 Which global centers have the best immunotherapy outcomes

Just tell me your focus.